Cambridge, MA | Oct 2023
Clear Scientific's antidote CS-1103 was featured in Medline Today highlighting its use against the dangerous and deadly combination of xylazine mixed with fentanyl. The xylazine/fentanyl combination was designated by the White House as an emerging threat to the United States, and the subject of a National Response Plan to coordinate whole-of-government response.
Jane Acri, PhD, Acting Deputy Director of NIDA's Division of Therapeutics and Medical Consequences, recently spoke about CS-1103 at the Mitigating Risks from Human Xylazine Exposure Meeting sponsored by the Reagan-Udall Foundation for the FDA. Dr. Acri expressed excitement in the potential of CS-1103 to have significant impact on the xylazine crisis, stating that "IV administration of CS-1103 increases xylazine clearance by six-fold in a 2-hour period in rats, and accelerates emergence from sedation by three-fold, going from 46 minutes to 16 minutes -- again, in rats. It also works when fentanyl is present, reversing both respiratory depression and sedation." Acri added, "The compound is moving forward into first-in-man clinical trials, hopefully, in 2024, and this, I think, has the potential to be a game-changer when and if it becomes clinically available, to provide another kind of treatment option."